Cholesterol 25-hydroxylase promotes efferocytosis and resolution of lung inflammation

Jennifer H. Madenspacher, … , Mark M. Wurfel, Michael B. Fessler


Alveolar macrophages (AM) play a central role in initiation and resolution of lung inflammation, but the integration of these opposing core functions is poorly understood. AM expression of cholesterol 25-hydroxylase (CH25H), the primary biosynthetic enzyme for 25-hydroxycholesterol (25HC), far exceeds the expression of macrophages in other tissues, but no role for CH25H has been defined in lung biology. As 25HC is an agonist for the antiinflammatory nuclear receptor, liver X receptor (LXR), we speculated that CH25H might regulate inflammatory homeostasis in the lung. Here, we show that, of natural oxysterols or sterols, 25HC is induced in the inflamed lung of mice and humans. _Ch25h−/−_ mice fail to induce 25HC and LXR target genes in the lung after LPS inhalation and exhibit delayed resolution of airway neutrophilia, which can be rescued by systemic treatment with either 25HC or synthetic LXR agonists. LXR-null mice also display delayed resolution, suggesting that native oxysterols promote resolution. During resolution, _Ch25h_ is induced in macrophages upon their encounter with apoptotic cells and is required for LXR-dependent prevention of AM lipid overload, induction of _Merk_, efferocytic resolution of airway neutrophilia, and induction of TGF-β. CH25H/25HC/LXR is, thus, an inducible metabolic axis that programs AMs for efferocytic resolution of inflammation.

Find the latest version:

https://jci.me/137189/pdf
Cholesterol 25-hydroxylase promotes efferocytosis and resolution of lung inflammation

Jennifer H. Madenspacher,1 Eric D. Morrell,2 Kymberly M. Gowdy,3,4 Jeffrey G. McDonald,5 Bonne M. Thompson,1 Ginger Muse,1 Jennifer Martinez,1 Seddon Thomas,1 Carmen Mikacenic,2 Jerry A. Nick,6 Edward Abraham,7 Stavros Garantziotis,1 Renee D. Stapleton,8 Julie M. Meacham,1 Mary Jane Thomassen,3 William J. Janssen,6 Donald N. Cook,1 Mark M. Wurfel,2 and Michael B. Fessler1

1Immunity, Inflammation and Disease Laboratory, National Institute of Environmental Health Sciences (NIEHS), NIH, Research Triangle Park, North Carolina, USA. 2Section of Pulmonary, Critical Care, and Sleep Medicine, Harborview Medical Center, Seattle, Washington, USA. 3Division of Pulmonary, Critical Care and Sleep Medicine, and 4Davis Heart and Lung Research Institute, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA. 5Department of Molecular Genetics, University of Texas Southwestern Medical Center, Dallas, Texas, USA. 6Department of Medicine, National Jewish Health, Denver, Colorado, USA. 7Department of Medicine, Leonard M. Miller School of Medicine, University of Miami, Miami, Florida, USA. 8Department of Medicine, Larner College of Medicine, University of Vermont, Burlington, Vermont, USA. 9Department of Internal Medicine, Brody School of Medicine, East Carolina University, Greenville, North Carolina, USA.

Introduction

Tissue-resident macrophages orchestrate initiation and resolution of inflammation. In response to environmental challenges such as LPS, macrophages generate temporal waves of mediators that recruit polymorphonuclear leukocytes (PMNs) and then monocytes from the circulation. The latter differentiate after arrival into macrophages with distinct transcriptional and metabolic profiles from their tissue-resident counterparts (1). Resident and recruited macrophages, instructed by an evolving cocktail of signals in the local inflammatory milieu, then drive resolution through phagocytic clearance of apoptotic cells (ACs) (i.e., efferocytosis) (2, 3). Binding and internalization of ACs engages antiinflammatory programs in macrophages (4, 5) and also feeds forward to sustain efferocytosis through activation of liver X receptor (LXR) and other transcription factors that upregulate efferocytic receptors, such as MERTK (6, 7).

In the special case of the lung, apoptotic PMNs must be quietly and efficiently cleared in order to preserve tissue integrity and vital gas exchange. However, resident alveolar macrophages (AMs) express a narrow complement of efferocytic receptors (MERTK and AXL; absent/low expression of other receptors; refs. 3, 8, 9) and...
have low efferocytic function compared with macrophages in other tissues (10, 11). Although AM efferocytosis increases after LPS exposure and is thought to be primarily driven by recruited CD11c\(^+\)CD11b\(^+\) macrophages (1–3), few of the local signals that augment AM efferocytosis during inflammation have been identified (12). Moreover, the intracellular signals within macrophages that link AC engagement to LXR and MERTK activation remain poorly defined.

Oxysterols (i.e., oxidized species of cholesterol), have been studied for many years as feedback inhibitors of cellular cholesterol accumulation through their activation of LXR (13). Although 25-hydroxycholesterol (25HC) has, in particular, long been used in cell-based studies, mice deleted for cholesterol 25-hydroxylase (Ch25h), encoding the primary 25HC-synthetic enzyme, have grossly normal lipid metabolism (14). Concentrations of 25HC in human tissues are also far lower than those of other oxysterols (15). Thus, for many years, the physiologic relevance of 25HC was questioned. Recently, however, it was discovered that LPS dramatically induces Ch25h (>100-fold) and 25HC (>80-fold) in cultured macrophages (16–19). 25HC has now been shown to have potent anti- and proinflammatory functions in different contexts, suppressing inflammasome activation (20) and supporting M2 macrophage programming (21), but also amplifying proinflammatory cytokine induction by TLR ligands (22). Collectively, these findings have suggested that Ch25h is an immune-response gene induced in both inflammatory and regulatory settings, and that CH25H and its product, 25HC, may thus have context-dependent (i.e., tissue microenvironment-dependent) functions.

In mice, Ch25h is by far most highly expressed in the lung (23). Remarkably, AM Ch25h expression exceeds that of macrophages in other tissues by > 10-fold (24). This suggested to us an important role for Ch25h in lung inflammation. Here, we report that 25HC is the only oxysterol induced by LPS in the mouse lung and that its induction requires Ch25h. AM Ch25h is induced robustly but transiently in resident AMs early in inflammation and also in recruited AMs later, during the resolution phase of inflammation. We show that Ch25h is induced in resolution-phase macrophages upon their encounter with ACs and that it is required for Mertk induction and LXR-dependent efferocytic resolution of neutrophilia. Suggesting relevance to humans, Ch25h is induced by LPS in human AMs, and 25HC is induced in the airspace of LPS-exposed human volunteers. Moreover, we show that, in acute respiratory distress syndrome (ARDS) patients, AM CH25H expression tracks with AM MERTK and bronchoalveolar lavage fluid (BALF) 25HC. Taken together, we identify CH25H/25HC/LXR as a temporally inducible metabolic axis that contributes to AM reprogramming for resolution of inflammation.

**Results**

LPS triggers robust and selective induction of 25HC in murine and human lung. LXR is an oxysterol-activated nuclear receptor that coordinately suppresses cellular cholesterol accumulation and inflammation. Upon sensing an excess of intracellular desmosterol or oxysterols (i.e., 24(S)HC; 25HC; 27HC), LXR induces genes that encode sterol efflux transporters (e.g., ATP-binding cassette a1 [Abc1a1, Abcg1]) and also transrepresses NF-kB (13). We have previously shown that treatment of mice with a synthetic LXR agonist reduces LPS-induced lung inflammation (25). Given this, we speculated that native oxysterols might also be induced in the lung following LPS and then act through autocrine or paracrine mechanisms to modulate inflammation through LXR. To this end, we exposed C57BL/6 mice to LPS aerosol and used liquid chromatography-mass spectrometry to screen BALF harvested at various time points for a wide panel of naturally occurring (oxy)sterols. Of 13 sterols measured, only 25HC was induced following LPS (Figure 1A and Supplemental Figure 1; supplemental material available online with this article; https://doi.org/10.1172/jci.insight.137189DS1). 25HC induction was remarkably robust, was completely Ch25h dependent, and was also observed in the serum of mice following LPS inhalation (Figure 1, A and B) and in the BALF of human volunteers 16 hours following bronchoscopic LPS instillation (Figure 1C). By contrast, 7α,25-HC, a downstream metabolite of 25HC that is inactive upon LXR but has chemoattractant activity through the receptor EBI2 (26), was undetectable (not shown).

Ch25h is very highly expressed in AMs compared with macrophages in other tissues (24). We found that Ch25h expression was ~35-fold higher in CD64\(^+\)F4/80\(^+\)CD11c\(^+\)CD11b\(^+\) resident AMs lavaged from the airspace of naive mice than in CD64\(^+\)Ly6C\(^+\) monocytes sorted from digests of naive lung parenchyma (Supplemental Figure 2). This suggests that signals in the alveolar space may induce Ch25h during AM differentiation. Naive Ch25h\(^+/−\) mice had normal AM counts and airspace cytokine levels (Supplemental Figure 3), suggesting that CH25H is not itself overtly required for AM differentiation.
Given the robust Ch25h-dependent induction of 25HC by LPS, we speculated that pulmonary Ch25h might be upregulated by LPS. We and others have shown that LPS induces Ch25h in cultured cells through a pathway involving the TLR4 adaptor TIR-domain–containing adapter–inducing IFN-β (TRIF) and downstream autocrine IFN-β signaling through its receptor, Ifnar (17, 18, 27). Consistent with this, we found that Ch25h was highly upregulated in WT murine lungs within 4 hours of LPS and that this was abrogated in Trif−/− mice and markedly reduced in Ifnar−/− mice (Figure 1, D and E). Pointing to an additional role for the TLR4 adaptor myeloid differentiation primary response 88 (MYD88), Ch25h induction was also abrogated in Myd88−/− mice (Figure 1F). Tissue fractionation studies confirmed that Ch25h was strongly induced by LPS in airspace leukocytes, as well as CD45+ cells (leukocytes) in the lung parenchyma, but not in lung parenchymal CD45−EpCAM+ (epithelial) cells (Figure 1G). LPS similarly upregulated CH25H in primary human AMs ex vivo (Figure 1H). In a high-dose model of LPS-induced lung injury with more protracted kinetics (peak inflammation, day 3; resolution, days 6–12), we confirmed that Ch25h was transiently upregulated in resident (CD64+F4/80+CD11c+CD11b+) AMs at peak inflammation, whereas recruited AMs (CD64+F4/80+CD11c+CD11b+) collected by BAL downregulated Ch25h during early resolution, followed by a progressive recovery of expression (Supplemental Figure 4). In a cohort of 30 ARDS patients, AM CH25H and BALF 25HC were correlated (r = 0.47, P < 0.01), suggesting that AMs may be an important...
source of 25HC in the alveolar space during clinical human lung injury (Supplemental Figure 5). Taken together, these findings indicate that Ch25h is a signature gene of AMs, that it is dynamically regulated in murine and human AM populations following LPS exposure, and that its product, 25HC, is unique among oxysterols in being induced and released in the inflamed lung.

**Defective resolution of inflammatory neutrophilia in Ch25h-null mice.** LPS inhalation triggers a self-limited inflammatory response in which cytokines/chemokines attract circulating PMNs to the airspace. In order to fully profile the effect of CH25H/25HC deficiency on induction and resolution of acute lung inflammation, we used a well-characterized low-dose LPS aerosol exposure model in which peak alveolar neutrophilia occurs by 24 hours after LPS and is then followed by clearance of PMNs by approximately 72 hours (25). Of interest, we found that Ch25h−/− mice had normal induction to peak neutrophilia but a defect in resolution of alveolar PMN counts (Figure 2A). A defect in PMN resolution was also observed following i.t. infection with the Gram-negative bacterium, Klebsiella pneumoniae (Figure 2B). No difference in K. pneumoniae burden (i.e., CFUs) was seen between Ch25h−/− and Ch25h+/+ lungs 24 hours after infection (data not shown). Moreover, indicating that the defect in resolution of neutrophilia in Ch25h−/− mice extends beyond the lung, persistent elevation of peritoneal cavity PMNs was also observed 4 days following i.p. injection with Brewer’s thioglycollate (Figure 2C), a time point during which resolution is underway in this model of neutrophilic peritonitis (28).

The LPS aerosol model has well-curated kinetics, in which most cytokines and CXCR2-active (PMN-attracting) chemokines peak in the BALF by about 2 hours and then largely extinguish by about 24 hours (25, 29). Consistent with the late-phase neutrophilia in Ch25h−/− mice deriving from a deficit in PMN clearance, and not from sustained chemokine-driven influx of blood PMNs into the alveolus, we found that cytokine levels were equivalent between strains at 2 hours but that select cytokines and chemokines — including several known to attract PMNs to the airspace and/or to support their intraalveolar survival (i.e., CXCL1, CXCL5, TNF-α, IL-6, GM-CSF) — were lower in Ch25h−/− mice than WT counterparts at later time points (Figure 2, D–G). Although Ch25h−/− macrophages are reported to have derepressed inflammasome-dependent production of IL-1β (20), we observed no difference in BALF IL-1β between the 2 strains at any time point. Surface expression of CXCR2 on peripheral blood PMNs was also not substantially different between the 2 strains at 24 or 48 hours after LPS (Supplemental Figure 6). Taken together, while these findings could be consistent with 25HC induction in the airspace acting to sustain alveolar levels of select cytokines, they did not suggest that Ch25h deletion prolongs PMN migration into the airway and, instead, pointed to a possible deficit in clearance of PMNs.

Ch25h is required for native activation of the LXR pathway in the inflamed lung. Although LPS reportedly suppresses LXR activity in cultured macrophages (30), we nonetheless questioned whether robust induction of endogenous 25HC might support native LXR activity during inflammation in vivo. Confirming its activity as a bone fide LXR agonist, we found that, similar to the synthetic LXR agonist TO901317 (13, 25), 25HC strongly induced the LXR target genes Abca1 and Abcg1 in murine peritoneal exudate macrophages (PEMs) and did so in an LXR-dependent manner (Figure 3A). In vivo (i.p.) treatment of mice with 25HC also induced multiple LXR target genes, as well as the genes encoding LXRα and -β themselves (Nr1h3 and Nr1h2, respectively) in the lungs of WT mice (Figures 3B). Given this, we speculated that the rapid and robust induction of native 25HC in the lungs of LPS-exposed WT but not Ch25h−/− mice might support native activation of LXR in the former strain. Indeed, consistent with this, we found that a panel of 4 LXR target genes plus Nr1h3 and Nr1h2 all displayed a rapid but transient induction in WT, but not Ch25h−/−, lung parenchyma following LPS (Figure 3C). This gene signature suggests that the robust 25HC induction observed in the alveolus in the early hours following LPS exposure supports a wave of native LXR pathway activity in the inflamed lung. This response, however, appears to extinguish before the resolution phase of neutrophilia.

Resolution deficit in Ch25h-null mice arises from LXR pathway insufficiency. We have reported that synthetic LXR agonists reduce LPS induction of airspace cytokines in mice (25). Given that Ch25h−/− mice displayed reduced BALF cytokines after LPS, we reasoned that deficient LXR activity could not explain this phenotype and that it, instead, likely reflected an LXR-independent function of 25HC (22). On the other hand, LXR activation has also been shown to augment efferocytic clearance of PMNs (7). We thus speculated that LXR insufficiency in Ch25h−/− mice might be responsible for compromising resolution of airway neutrophilia. Consistent with this, we found that systemic treatment of Ch25h−/− but not WT mice with the selective synthetic LXR agonist GW3965 (13) reduced late-phase alveolar neutrophilia after LPS.
(48 hours after LPS), essentially normalizing PMN counts (Figure 4A). Moreover, systemic treatment of Ch25h−/− mice with 25HC rescued late-phase alveolar neutrophilia after LPS, whereas it had no effect in LXR-deficient mice (Figure 4B), indicating that 25HC accelerates resolution via LXR. 25HC can be further processed by Cyp7b1 into 7α,25-HC (26). However, we found that Ebi2−/− mice did not phenocopy Ch25h−/− mice and, instead, exhibited a modest reduction in late-phase alveolar neutrophilia (Figure 4C). This, along with our inability to detect 7α,25-HC in the LPS-exposed lung, suggests that the failure of Ch25h−/− mice to resolve neutrophilia does not stem from 7α,25-HC deficiency.

Of interest, LXRα/β-deficient mice (Figure 4B), as well as mice singly deleted for either LXRα or LXRβ (Figure 4D), all displayed persistent late-phase alveolar neutrophilia compared with WT counterparts, supporting the notion that LXR, presumably responsive to endogenous agonists such as 25HC, is required for resolution of alveolar neutrophilia. However, LXR-deficient mice, unlike Ch25h−/− mice, also had elevated peak neutrophilia 24 hours after LPS (Figure 4D). Taken together, these findings suggest that native LXR agonists other than, or in combination with, 25HC act to repress the induction phase of

**Figure 2. CH25H is required for resolution of neutrophilia.** (A and B) Ch25h+/+ and Ch25h−/− mice were exposed to LPS (A) or K. pneumoniae (B) by inhalation and then BAL polymorphonuclear neutrophils (PMNs) were quantified at the indicated times (n = 6/genotype/time point). (C) Peritoneal PMNs were quantified in Ch25h+/+ and Ch25h−/− mice 4 days following i.p. injection of Brewer’s thioglycollate (n = 4/genotype). (D–F) BALF was collected from Ch25h+/+ and Ch25h−/− mice (n = 4–6/genotype/time point) at 2 hours (D), 8 hours (E), and 24 hours (F) after inhalation of LPS and analyzed for cytokine levels by multiplex assay. (G) BALF was collected from mice (n = 3–5/genotype/time point) at the indicated times following inhaled LPS and analyzed by ELISA for CXCL5 concentration. Data are mean ± SEM and are representative of 2–3 independent experiments. *P < 0.05 by unpaired t-test.
alveolar neutrophilia, whereas 25HC deficiency is sufficient to compromise late-phase LXR-dependent clearance of PMNs from the airspace.

Ch25h deletion impairs macrophage cholesterol homeostasis and efferocytosis. Having established that the late-phase neutrophilia in Ch25h–/– mice is corrected by pharmacologic activation of LXR, and that 25HC supplementation also rescues the neutrophilia in an LXR-dependent fashion, we speculated that LXR pathway insufficiency in a pulmonary cell type was responsible for the resolution deficit. Chimeric mice generated by bone marrow transfer from WT or Ch25h–/– donors into WT or Ch25h–/– recipients revealed that Ch25h deletion in hematopoietic cells was sufficient to increase late-phase alveolar neutrophilia (Figure 5A). This, along with our finding that LPS robustly induces Ch25h in AMs (Figure 1), suggested that deficient AM 25HC might underlie the resolution failure in Ch25h-deficient mice.

AMs harvested from Ch25h–/– mice 48 hours after LPS had a grossly “foamy” appearance to their cytoplasm that stained positive with Oil Red O, suggesting cellular overload with neutral lipid (i.e., cholesterol) (Figure 5B). This is reminiscent of the increased macrophage foam cells reported in the lungs of mice deleted for the LXR targets Abca1 and Abcg1 (31, 32). Macrophages harvested from resolving peritoneal exudates similarly displayed an increased frequency of conversion to lipid-laden foam cells (Figure 5C). Suggesting that the lipid overload stemmed from LXR pathway (cholesterol efflux) insufficiency, freshly harvested PEMs from Ch25h–/– mice displayed deficient expression of a panel of LXR target genes, including Abca1 and Abcg1 (Figure 5D). Taken with our finding that 25HC is uniquely induced in the lung by LPS, the provocation of foam cells by Ch25h deletion suggests that, among native oxysterols, 25HC may be uniquely required for preventing conversion of inflammatory macrophages into foam cells. Moreover, these findings suggested to us that AM dysfunction stemming from LXR insufficiency might underlie the failure to resolve neutrophilia in Ch25h–/– mice.

Figure 3. 25HC activates LXR in the lung. (A) WT peritoneal exudate macrophages (PEMs) were exposed for 16 hours to 25HC or LXR agonist TO901317 (T1317) in the presence or absence of the LXR antagonist GSK2033 and were then quantified by qPCR for Abca1 or Abcg1 mRNA (fold change [FC], n = 3/condition; ND, not detected). (B) WT mice were treated i.p. with 25HC or vehicle (Veh.), and then lung tissue was analyzed by qPCR for the targets shown (n = 8–10/condition). (C) Ch25h+/+ and Ch25h–/– mice were exposed to inhaled LPS, and lung tissue was analyzed by qPCR for the indicated targets at the times shown (n = 4–6/genotype/time point). Data are mean ± SEM and are representative of 2–3 independent experiments. *P < 0.05; **P < 0.01 by unpaired t test.
Macrophage LXR augments efferocytic clearance of apoptotic PMNs, upregulating Merk and Abca1 (thereby effluxing cholesterol from internalized ACs) in a feedforward fashion (6, 7). Among efferocytic receptors, MERTK has been shown to play a primary role in efferocytosis by both AMs and PEMs (3, 10, 33), but the details of dynamic regulation of Merk and Abca1 by ACs — in particular, whether or not macrophage LXR is activated by sterols from internalized ACs — remain controversial (6, 34, 35). The reduced Merk expression in macrophages harvested from resolving peritoneal exudates of Ch25h−/− mice (Figure 5D) suggested that their efferocytic function might be defective. Ex vivo treatment of murine macrophages with 25HC robustly induced Merk in an LXR-dependent fashion (Figure 5E) and in vivo (i.p.) treatment of WT mice induced Merk in lung tissue (Figure 5F), collectively supporting the notion that 25HC deficiency in Ch25h−/− mice could cause deficient pulmonary macrophage expression of Merk.

In order to directly assay in vivo efferocytic function of AMs in Ch25h−/− mice during the resolution phase of inflammation, we instilled apoptotic thymocytes i.t. 48 hours after LPS; we then lavaged the airspace 90 minutes later and manually counted the frequency of AMs that had internalized ACs (36). Efferocytosis was indeed significantly decreased (mean reduction, ~41%) in AMs from Ch25h−/− mice (Figure 5G). Consistent with deficient native efferocytosis of PMNs contributing to the late-phase alveolar neutrophilia of Ch25h−/− mice, we also observed an increased frequency of uncleared apoptotic PMNs in the airspace of Ch25h−/− mice 48 hours after LPS (Figure 5H). Of interest, Ch25h−/− macrophages, by contrast, displayed normal internalization of bacterial bioparticles (Figure 5I). Ch25h deletion, therefore, does not globally compromise macrophage phagocytosis of all cargo. Ch25h−/− mice, as well as mice deleted for either LXRα or LXRβ, all had increased accumulation of macrophages in the alveolar space after LPS (Supplemental Figure 7), ruling out macrophage deficiency as a contributing factor to reduced efferocytic clearance of cell corpses from the airspace.

Ch25h is induced in efferocytic macrophages and required for Merk upregulation. Aiming to better define the role of CH25H in efferocytosis, we next focused our attention directly on macrophage CH25H during efferocytic engagement of ACs. Given similar efferocytic receptor utilization in AMs and PEMs (in particular, their primary reliance on MERTK; refs. 3, 8, 33) and the relative ease of harvesting large numbers of the latter cell type, we used PEMs in our studies. Of interest, ACs (irradiated Jurkat cells; ref. 36) induced

Figure 4. Defective resolution in Ch25h-null mice arises from LXR insufficiency. (A and B) Mice of the indicated genotypes were pretreated i.p. with either synthetic LXR agonist GW3965 (A) or 25HC (B) (or vehicle [Veh] control), exposed to inhaled LPS, and then evaluated for airway PMN count 48 hours later (n = 5/genotype/time point). (C and D) Airway PMNs were quantified in mice of the indicated genotypes at various times following inhalation of LPS (n = 5–8/genotype/time point). Data are mean ± SEM and are representative of 2–3 independent experiments. *P < 0.05; **P < 0.01 by unpaired t test.
Ch25h in WT murine macrophages (Figure 6A), indicating — together with our finding of progressive Ch25h induction in resolution-phase recruited AMs (Supplemental Figure 4) — that Ch25h is induced not only in inflammatory, but also in regulatory settings. Unlike the case for Ch25h induction by LPS (Figure 1), AC induction of Ch25h was Ifnar independent (Figure 6B).

Efferocytic receptors of the TYRO3/AXL/MERTK (TAM) family engage ACs indirectly via growth arrest specific 6 (GAS6), a secreted protein that bridges phosphatidylserine (PS) on ACs to macrophage TAMs, activating the latter (11). Treatment of macrophages with recombinant GAS6 induced sustained Ch25h upregulation of a similar magnitude to that induced by ACs (Figure 6C), suggesting that AC internalization may not be required for Ch25h induction and that Ch25h may instead be upregulated via signaling initiated from the cell surface. Of interest, we found that AC induction of both Mertk and Abca1 was abrogated in Ch25h null macrophages (Figure 6D), suggesting that macrophage 25HC is required for induction of these LXR targets during efferocytosis. By contrast, induction of Axl, an LXR-independent TAM receptor (6), was Ch25h independent (Figure 6E). Compared with...
control phosphatidylcholine (PC) liposomes, AC-mimetic PS liposomes induced Mertk and Abca1, and this was also muted in Ch25h–/– macrophages (Figure 6F). This suggests that, like Ch25h induction, CH25H-dependent induction of LXR target genes in efferocytic macrophages does not require internalization of AC cargo. In AMs harvested from ARDS patients, we found a significant correlation between CH25H and MERTK expression ($r = 0.69$, $P < 0.01$) (Figure 6G), suggesting that native 25HC may also regulate MERTK expression in humans.
Efferocytosis not only guards against proinflammatory postapoptotic lysis of dead cells, but it also programs macrophages to express TGF-β and other antiinflammatory mediators (5). ACs modestly increased Tgfb1 mRNA in WT but not Ch25h−/− macrophages (Figure 6H). While we did not detect TGF-β in BALF in our low-dose LPS aerosol model, Ch25h−/− mice had lower BALF TGF-β than WT counterparts during the resolution phase following inhalation of a high-dose (3 mg/mL) LPS aerosol (Figure 6I). We also found that macrophages freshly harvested from peritoneal exudates of Ch25h−/− mice had reduced Tgfb1 expression (Figure 6J). Macrophage CH25H is, thus, also required to support the antiinflammatory functional consequences of efferocytosis during resolution of acute inflammation.

Discussion

Efferocytic macrophage populations and the clearance receptors they use differ across tissues, and within tissues, they differ between homeostatic and injury settings (2, 9, 37–39). Here, we identify CH25H/25HC as a metabolic axis that is induced in AMs early in inflammation, but also late in inflammation after PMN apoptosis has commenced, when it supports regulatory efferocytosis and TGF-β induction. We posit that, in both cases, Ch25h, encoding a lipid hydroxylase, is induced by cell signals initiated by macrophage sensing of membrane lipids — bacterial LPS and AC PS, respectively. Inflammatory versus regulatory Ch25h induction may, however, largely derive from distinct AM pools. Resident AMs, as sentinels of the alveolus, upregulate Ch25h rapidly in response to LPS and induce a transient LXR signature in lung before substantial influx of PMNs to the airspace. Consistent with reports that recruited AMs, which appear days later, are primarily responsible for efferocytosis (2), we find that, during resolution, Ch25h is selectively and progressively upregulated in these cells (Supplemental Figure 4). This suggests that AC-induced regulatory Ch25h/25HC may derive from recruited AMs, contemporaneous with the accumulation of ACs after peak PMN influx. Our findings, however, do not prove which pool of macrophage CH25H is most important to resolution, especially given that Ch25h expression is lower in recruited than in resident macrophages. As the contribution of CH25H to resolution of neutrophilia is partial, the physiological significance of the CH25H/25HC/LXR axis is also uncertain. Nonetheless, our rescue studies suggest potential for exogenous 25HC and synthetic LXR agonists as proresolving therapeutics, at least in low-CH25H states and perhaps other disease conditions with deficient efferocytosis.

The local factors that determine the high expression of Ch25h in AMs remain poorly defined. The transcription factor KLF4 is a candidate, as it has been shown to transactivate Ch25h in endothelial cells (40) and was recently identified as a master regulator of efferocytosis that is highly expressed by AMs (9, 41). Of interest, activating transcription factor 3, which reportedly represses Ch25h, is expressed at much lower levels in AMs than in pulmonary interstitial macrophages or in macrophages from several other tissues (24). Recent reports indicate that resident AMs are endowed with mechanisms to cope with local 25HC. The sterol efflux transporter ABCG1, in particular, plays a key role in mobilizing 25HC from AMs and preventing pulmonary 25HC overload (42). Neutral cholesterol ester hydrolase 1 has also been shown to protect cells from 25HC-induced ER stress (43) and is reportedly much more highly expressed in AMs than in macrophages from other tissues (44). It is, thus, intriguing to consider that AMs may be metabolically buffered against 25HC. Despite our findings using bone marrow chimeric mice, we do not exclude a possible role for endothelial CH25H. Moreover, cell-specific roles for CH25H likely differ in the human lung, where Ch25h expression has been reported in both AMs and pneumocytes of subjects with COPD (45).

We found that CH25H is required to prevent transformation of postinflammatory macrophages into lipid-laden foam cells. This suggests that 25HC, among oxysterols, may be uniquely required during resolution for coordinately supporting cholesterol efflux and efferocytosis through LXR. This distinguishes it from desmosterol, which accumulates in foam cells during dyslipidemia and activates LXR (46). Resolution phase 25HC may also possibly prevent cellular lipid overload by suppressing cholesterol biosynthesis (26). These protective functions of native Ch25h/25HC likely depend on contextual signals that are not adequately modeled by exogenous 25HC, given that treatment of bone marrow–derived macrophages and fibroblasts with 25HC reportedly promotes cytosolic lipid body accumulation (47).

Although it has been proposed that the TAM receptor AXL predominates in inflammatory settings and MERTK in regulatory settings (48), several reports have documented suppressive roles for MERTK in acute inflammation (49–51), as well as in postinflammatory efferocytosis, including in the lung (3). Despite its cleavage by proteases early in inflammation, MERTK is progressively induced (49, 52) and activated (49, 53) — likely due, at least in part, to feedforward effects of efferocytosis. Reports to date have differed on whether...
(6, 7) or not (35) the sterol load of internalized ACs drives LXR-dependent induction of MerTk and other target genes. AC internalization may not be required for induction of ABCA1 (35) or repression of cytokines (5). Here, we show for the first time to our knowledge that macrophage Ch25h plays a role in efferocytosis and its transcriptional consequences. Our finding that Ch25h is also required for MerTk induction by liposomal PS suggests that AC internalization may be dispensable. Alternatively, given that Ch25h is itself a LXR target (54), it is also possible that Ch25h/25HC is required to relay and amplify primary activation of LXR by the internalized AC. Whether basal levels of 25HC are permissive for efferocytosis or whether de novo generation of 25HC is required remains unclear.

Our studies leave open the possibility of additional roles for 25HC in AC clearance. For example, 25HC reportedly activates RAC (55), a GTPase that plays a key role in efferocytosis (56). In addition, given that LPS upregulates Ch25h in PMNs (57), and 25HC is chemoattractive (58), it is intriguing to consider that 25HC may also possibly serve as a “find me” signal for efferocytic macrophages. 25HC also has membrane-disordering properties (59); thus, 25HC could also conceivably alter the palatability of ACs to efferocytic macrophages. Finally, it is possible that CH25H/25HC may also impact important mechanisms of resolution beyond efferocytosis, such as generation of specialized proresolving lipid mediators (e.g., resolvins) and recruitment of Tregs to the lung.

LXR-null and MERTK-null mice both reportedly develop spontaneous inflammation and autoimmune disease with age due to defective efferocytosis in their tissues (6, 60). In contrast with this, we found that neither male nor female Ch25h−/− mice aged out to 1+ years developed pathology in any of several tissues screened (e.g., kidney, lung, lymph nodes, pancreas, heart, liver, spleen, and skeletal muscle). This suggests that, while CH25H is required for postinflammatory efferocytosis, it may be dispensable for homeostatic clearance of ACs in the steady state.

In closing, we add 25HC to the list of paracrine lipids that program efferocytosis during resolution of inflammation. Future studies are warranted to better define whether the downstream effects of 25HC on inflammation and injury are dissociable and whether 25HC may be either an informative biomarker or an intervenable target in human lung disease.

Methods

Reagents. E. coli 0111:B4 LPS, penicillin, and streptomycin were from MilliporeSigma. K. pneumoniae 43816 (serotype 2), DMEM, and FBS were from American Type Culture Collection. GW3695 (MilliporeSigma), T0901317 (Cayman Chemical), 25HC (MilliporeSigma), cholesterol (MilliporeSigma), GS2033 (MilliporeSigma), GAS6 (R&D), and PS and PC (Avanti Polar Lipids) were purchased. The Bio-Rad protein assay was used (catalog 5000006).

Mice. Female and male mice, 7–10 weeks old and weighing 18–22 g, were used. Ch25h−/− mice were produced as described (16). C57BL/6, Myd88−/−, and Ifnar−/− mice were from the Jackson Laboratory. Trif−/− mice were as described (27). Nr1h2−/− and Nr1h3−/− mice were provided by David Mangelsdorf (University of Texas Southwestern Medical Center) and were intercrossed to produce Nr1h2−/−Nr1h3−/− mice. All aforementioned strains were ≥ 8 generations backcrossed to C57BL/6. In selected experiments (e.g., alveolar neutrophil counts after LPS), littermate controls were used. For other experiments, C57BL/6 controls were used. Ebi2−/− mice (i.e., B6;129S5-Gpr183mul/Mmucd, identification number 032339-UCD) were obtained from the Mutant Mouse Regional Resource Center, a NIH-funded strain repository, and were donated to the MMRRC by Genentech Inc. Littermate controls were used exclusively for this strain.

In vivo murine exposures. Exposure to aerosolized LPS (300 μg/mL or 3 mg/mL, 30 minutes) was as previously described (25). K. pneumoniae (2000 CFU/50 μL) was delivered to lung by oropharyngeal aspiration during isoflurane anesthesia (31). In some studies, mice were treated i.p. with 50 mg/kg 25HC or vehicle (hydroxypropyl-β-cyclodextrin; Cyclo Therapeutics Inc.) at −24, −2, and +24 hours in relation to LPS exposure or sacrifice without exposure. Apoptotic thymocytes were delivered to the lungs of mice 48 hours after LPS inhalation, as previously reported (36). Briefly, thymocytes harvested from thymi of −4-week-old C57BL/6 mice were exposed to ultraviolet radiation (312 nm) for 5 minutes, followed by culture in RPMI 1640 with 10% FBS at 37°C in 5% CO2 for 3 hours, and were confirmed to be > 90% annexin V+. Thymocytes (1 × 107 in 50 μL) were then delivered to the mouse lung by oropharyngeal aspiration during isoflurane anesthesia. At 90 minutes after thymocyte treatment, BAL was performed, and cells were centrifuged onto slides and stained using Hema-3. The efferocytic index was then manually quantified as the number of macrophages with internalized apoptotic bodies divided by the number of macrophages counted, multiplied by 100. A minimum of 200 macrophages were counted.
Human experimental studies. BAL samples from a previous study of normal healthy volunteers exposed to intrapulmonary LPS were analyzed (61). Briefly, participants were given LPS (4 ng/kg body weight; *E. coli* 0:113 LPS [NIH] in 10 mL saline) by bronchoscopic subsegmental instillation. LPS was randomized to either the lingula or right middle lobe and was immediately followed by 10 mL sterile saline deposition into a contralateral subsegment. A second bronchoscopy was performed 16 hours later, at which time both LPS- and saline-exposed subsegments underwent BAL with 150 mL saline. The BALF was then stored at –80°C until further analysis. In separate studies, normal healthy volunteers underwent BAL for collection of AMs.

Acute lung injury/ARDS patient cohort studies. BALF samples analyzed were previously collected from subjects who were enrolled at 5 North American centers for the Phase II Randomized Placebo-controlled Trial of Omega-3 Fatty Acids for the Treatment of Acute Lung Injury trial conducted from 2006–2008 (62), as previously described (63). Enrollment into the trial occurred within 48 hours of ARDS onset. All samples used for this study were obtained from subjects before they received treatment or placebo. A subset of patients had AMs purified by negative selection using antibody-labeled microbeads for CD3, CD15, CD19, CD235a, CD294, and CD326. RNA was extracted from purified AMs and hybridized to an Illumina HumanRef-8 Beadchip inclusive of 18,415 genes. Raw microarray data underwent variance stabilization and quantile normalization using the Bioconductor package *lumi* (64). The data have been deposited in the National Center for Biotechnology Information/Gene Expression Omnibus (GEO) under accession number GSE89953.

Generation of bone marrow chimeric mice. Bone marrow chimeric mice were generated as previously reported (31). Briefly, *Ch25*+/− mice congenic for CD45 (stock no. 002014; Jackson Laboratory) were used. Recipients were irradiated (900 rad) by a Model 431 irradiator using a 137Cs source (JL Shepherd and Associates). Within 4 hours after irradiation, bone marrow (2 × 10⁶ cells) from femurs and tibias of donor mice was injected i.v. into recipients. The efficiency of donor stem cell engraftment was determined by flow cytometry for CD45.1 (BioLegend, 110718) (∼9 weeks after marrow transfer on circulating cells) and analyzed using FlowJo (Tree Star Inc.) and FCS Express (De Novo Software) software.

Resident AMs (CD64+F4/80+CD11chiCD11bloSiglec-Fhi), recruited AMs (CD64+F4/80+CD11chiCD11bloSiglec-Flo), and lung parenchymal monocytes (CD64−SSCloLy6Chi) were identified and purified by fluorescence-activated cell sorting, as previously reported (1).

Murine BALF collection and analysis. BALF was collected immediately following sacrifice, and cells counts were performed as previously described (25). Total protein was quantified by the method of Bradford (31). Mass spectrometric quantitation of oxysterols. Sterols and oxysterols were quantified as previously described (16). Briefly, BALF and plasma were extracted with organic solvents, and sterols and oxysterols were quantified on a 4000 QTRAP liquid chromatography mass spectrometer (Applied Biosystems) (65).

Preparation of liposomes. Liposomes composed of either 100% PC or 70% PC/30% PS were generated by lipid extrusion as previously described (66). Briefly, the lyophilized lipids were reconstituted in chlороform and then dried under a gentle stream of nitrogen gas. After this, the lipid sheets were rehydrated forming unilamellar vesicles that were extruded via sonication and multiple passages through a Hamilton syringe.

Cell harvests and culture. Mouse bone marrow–derived macrophages were prepared and cultured in DMEM containing 10% (v/v) FBS and 10% (v/v) L cell–conditioned medium as a source of M-CSF for 5 days. PEMs were harvested by peritoneal lavage 96 hours after i.p. injection of Brewer’s thioglycollate (2 mL, 4% solution). PEMs were cocultured with either viable or apoptotic Jurkat cells at a 5:1 Jurkat/PEM ratio. Apoptosis was induced by UV at 60 mJ/cm², followed by incubation in complete media at 37°C for 2 hours. In other experiments, PEMs were treated with 400 μg/mL of either PC or PC/PS liposomes for 4 hours, after which RNA was collected for analysis.

Evaluation of foam cells. Lavage cells from the airway or peritoneum were cytospun onto a slide, stained with Oil Red O, and then manually counted for stain-positive foam cells.

Cytokine analysis. Cytokines were quantified in mice by multiplex assay (Bio-Plex, Bio-Rad) or by ELISA (CXCL5, TGF-β; R&D).

Flow cytometry and cell sorting. Lung was digested/disaggregated as previously reported (67). Anti-F4/80 (PE, 123116; APC, 123110), -CD11c (PE-Cy5, 117316), -CXCR2 (PE-Cy5.5, 129103), -CD45 (PE, 103105), -EpCAM (APC, 118212), and isotype control antibodies (catalog 400907) were from BioLegend. Cells were stained and fixed with 2% paraformaldehyde/PBS. Flow cytometry was performed using an LSR II (BD Biosciences) and analyzed using FlowJo (Tree Star Inc.) and FCS Express (De Novo Software) software. Resident AMs (CD64*F4/80*CD11c*CD11b*Siglec-F*), recruited AMs (CD64*F4/80*CD11c*CD11b*Siglec-F*), and lung parenchymal monocytes (CD64*SSCloLy6C*) were identified and purified by fluorescence-activated cell sorting, as previously reported (1).
**RNA-Sequencing (Seq)**. RNA-Seq and downstream analysis was performed as previously reported (1). The data have been deposited in the National Center for Biotechnology Information/GEO under accession number GSE94749.

**Assessment of apoptosis**. PMNs (Ly6G⁺; BioLegend, 127610) lavaged from the murine airway were incubated (60 minutes, 37°C) ex vivo with 1 μL (1:50 DMSO) of FLIVO, a cell-permeant fluorescent poly-caspase activity reporter (Immunochemistry); they were then washed twice (0.5% BSA in 1× PBS, pH 7.4). Fluorescence signal was quantified by flow cytometry.

**RNA isolation and quantitative PCR**. RNA was isolated by RNEasy kit (QIAGEN). Complementary DNAs (cDNA) was generated from 1.5 μg of purified RNA using TaqMan reverse transcription reagents from Applied Biosystems. Real-time PCR was performed in triplicate with TaqMan PCR Mix (Applied Biosystems) in the HT7900 ABI sequence Detection System (Applied Biosystems). Pre-designed primers were purchased from Thermo Fisher Scientific: Nr1h2 (Mm00437265_g1); Nr1h3 (Mm00443451_m1); Abca1 (Mm00442646_m1); Abcg1 (Mm00437390_m1); Ch25h (Mm00515486_s1); Sreb1 (Mm00550338_m1); Axl (Mm00437221_m1); Mertk (Mm00434920_m1); Tgfβ1 (Mm01178820_m1); Gapdh (Mm99999915_g1), CH25H (Hs02379634_s1); and GUSB (Hs00939627_m1). Gene expression was normalized to Gapdh in analyses of mouse cells/tissues and normalized to GUSB in the studies involving ex vivo exposure of human AMs.

**Histopathologic analysis**. Tissues were fixed in 10% neutral-buffered formalin, trimmed, processed for paraffin, embedded, sectioned (5 μm), and stained with H&E. Slides were scanned using an Aperio ScanScope XT Scanner (Aperio Technologies Inc.). Tissues (kidney, lung, spleen, thymus, mesenteric lymph node, submandibular lymph node, heart, pancreas, liver, gall bladder, and skeletal muscle) of naive ~1-year-old Ch25h⁺/+ and Ch25h⁻/⁻ mice were evaluated for pathology by a board-certified veterinary pathologist blinded to genotype.

**Statistics**. For murine cell and animal studies, analyses were performed using GraphPad Prism software. Data are represented as mean ± SEM. Two-tailed Student’s t tests were applied for comparisons of 2 groups, and 1-way ANOVA was used for comparisons of > 2 groups. For the patient studies, 25HC concentration and microarray probe intensities were analyzed as continuous variables after log, transformation given the distribution of the data. Eighteen of the 81 BALF specimens had a 25HC concentration below the lower limit of detection (LLOD) of 0.05 ng/mL. These specimens were assigned a 25HC concentration of half the LLOD. A Pearson's test was used to identify correlations between AM CH25H log₂ probe intensity and AM MERTK log₂ probe intensity, as well as AM CH25H log₂ probe intensity and log₂ 25HC BALF concentration. Analyses were conducted using GraphPad Prism statistical software or R version 3.5.1. For all tests, P < 0.05 was considered significant.

**Study approval**. All rodent experiments were performed in accordance with the Animal Welfare Act and the US Public Health Service Policy on Humane Care and Use of Laboratory Animals after review by the Animal Care and Use Committee of the NIEHS. For the human bronchoscopic LPS studies, approval was obtained from the Colorado Multiple IRB, and informed consent was provided according to the Declaration of Helsinki. For studies in which AMs were retrieved by BAL, normal healthy volunteers completed informed consent under approval of NIEHS IRB protocol no. 11-E-0006. For the fish oil ARDS trial, participants were enrolled at 5 North American centers (62). Informed consent was obtained before study enrollment; human subject committees at each site approved the trial, as did a Data Safety Monitoring Board appointed by the National Heart, Lung, and Blood Institute (NHLBI).

**Author contributions**

JHM, KMG, ST, JAN, EA, SG, JMM, MJT, WJJ, DNC, and MBF designed and conducted experiments, analyzed and interpreted the data, and contributed to writing of the manuscript. EDM, JGM, BMT, CM, RDS, and MMW analyzed and interpreted the data and contributed to writing of the manuscript. GM and JM prepared essential reagents and contributed to the writing of the manuscript.

**Acknowledgments**

The authors thank the NIEHS Flow Cytometry Core and Ligon Perrow for assistance with animal husbandry. This research was supported by the Intramural Research Program of the NIH (NIH), NIEHS (Z01 ES102005), and by NIH National Heart, Lung, and Blood Institute (P50 HL073996 and K23 HL144916).
Address correspondence to: Michael B. Fessler, National Institute of Environmental Health Sciences, 111 T.W. Alexander Drive, P.O. Box 12233, MD D2-01, Research Triangle Park, North Carolina 27709, USA. Phone: 984.287.4081; Email: fesslerm@niehs.nih.gov.


31. Draper DW, Madenspacher JH, Dixon D, King DH, Remaley AT, Fessler MB. ATP-binding cassette transporter G1 deficiency